Repligen (RGEN)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$167.60-1.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · RGEN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 225.3% |
| Our one-year growth estimate | diamond | 16.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 208.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 25 industry peers
RGEN — Chair transition
Dated 2026-01-06
Chair of the Board — Tony J. Hunt: The filing announces the planned retirement of the Executive Chair and the election of a named successor, representing an orderly succession rather than a sudden loss of leadership.
Why it matters: Lower guidance would mean weaker demand or problems in operations.
Worry ifQ2 revenue guidance was less than $803 million.
Less concerning ifQ2 revenue guidance reported at $803 million or higher.
Why it matters: Falling below this level may raise worries about making money and managing costs.
Worry ifAdjusted EPS was below $2.03.
Less concerning ifAdjusted EPS was above $2.03.
Why it matters: Keeping this margin shows good cost control and efficiency. These are important for long-term success.
Supportive ifOperating margin was between 15.7% and 16.0%.
Worry ifOperating margin was less than 15.7%.
Why it matters: If revenue growth drops, it could signal a slowdown in the sector and hurt Repligen's outlook.
Worry ifRevenue growth falls below the median growth rate for the sector.
Less concerning ifRevenue growth is still above average. This shows continued strength.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$166 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $464 loss on $10,000 · 4.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,028 loss on $10,000 · 40.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Doing well in this partnership could improve Repligen's market position in Asia.
Supportive ifAnnouncement of new orders or revenue from the China partnership.
Worry ifNo big updates or orders came from the China partnership.
Why it matters: This would indicate Repligen is not on track to meet its growth target for the year.
Worry ifQ3 organic revenue growth was below 10.5%.
Less concerning ifQ3 organic revenue growth reported at or above 10.5%.
Why it matters: Missing this target shows problems with making money, even with revenue growth.
Worry ifAdjusted EPS reported below $2.03 for FY26.
Less concerning ifAdjusted EPS reported at or above $2.03 for FY26.
Why it matters: Finishing this project will improve Repligen's place in the cell therapy market.
Supportive ifAcquisition of BioLife Solutions closes by the end of Q4 2026.
Worry ifAcquisition fails to close by the end of Q4 2026.
Why it matters: This means Repligen may have trouble keeping its profit goals.
Worry ifQ3 operating margin was below 15.7%.
Less concerning ifQ3 operating margin was at or above 15.7%.